Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Risedronate and Chemotherapy in Triple-Negative Breast Cancer
NCT07471815Phase 2Active, not recruiting
- Sponsor
- Harbin Medical University
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, risedronate in triple-negative breast cancer (TNBC), sponsored by Harbin Medical University. Started Mar 2026; status: active, not recruiting.
02
Drugs
camrelizumabrisedronate
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07471815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07471815.